Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 31Completed 7Recruiting 2Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 195Nivolumab 146Carboplatin 134Specimen Handling 130Magnetic Resonance Spectroscopy 115Cyclophosphamide 109Paclitaxel 106Cisplatin 98Biopsy 97Radiotherapy 90durvalumab 81Dexamethasone 79atezolizumab 73Ipilimumab 62Gemcitabine 62Rituximab 59Doxorubicin 59Lenalidomide 55Docetaxel 55olaparib 52Bevacizumab 51Capecitabine 50Fluorouracil 49Etoposide 49Radiation 47Oxaliplatin 47Radiosurgery 42Prednisone 42venetoclax 41Taxes 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Active not recruiting × icotinib × Clear all
NCT05007938 2024-08-23

Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer

Betta Pharmaceuticals Co., Ltd.

Phase 2 Active not recruiting
30 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡